Abivax SA has a consensus price target of $34.2 based on the ratings of 5 analysts. The high is $50 issued by Guggenheim on April 29, 2024. The low is $16 issued by Morgan Stanley on April 11, 2024. The 3 most-recent analyst ratings were released by BTIG, Guggenheim, and Piper Sandler on May 20, 2024, April 29, 2024, and April 29, 2024, respectively. With an average price target of $45 between BTIG, Guggenheim, and Piper Sandler, there's an implied 238.35% upside for Abivax SA from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/20/2024 | Buy Now | 223.31% | BTIG | Julian Harrison | → $43 | Initiates | → Buy | Get Alert |
04/29/2024 | Buy Now | 275.94% | Guggenheim | Yatin Suneja | → $50 | Initiates | → Buy | Get Alert |
04/29/2024 | Buy Now | 215.79% | Piper Sandler | Christopher Raymond | → $42 | Initiates | → Overweight | Get Alert |
04/11/2024 | Buy Now | 20.3% | Morgan Stanley | Vikram Purohit | $15 → $16 | Maintains | Equal-Weight | Get Alert |
11/14/2023 | Buy Now | 50.38% | Leerink Partners | Thomas Smith | → $20 | Initiates | → Outperform | Get Alert |
11/14/2023 | Buy Now | 12.78% | Morgan Stanley | Vikram Purohit | → $15 | Initiates | → Equal-Weight | Get Alert |
The latest price target for Abivax (NASDAQ:ABVX) was reported by BTIG on May 20, 2024. The analyst firm set a price target for $43.00 expecting ABVX to rise to within 12 months (a possible 223.31% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Abivax (NASDAQ:ABVX) was provided by BTIG, and Abivax initiated their buy rating.
There is no last upgrade for Abivax
There is no last downgrade for Abivax.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Abivax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Abivax was filed on May 20, 2024 so you should expect the next rating to be made available sometime around May 20, 2025.
While ratings are subjective and will change, the latest Abivax (ABVX) rating was a initiated with a price target of $0.00 to $43.00. The current price Abivax (ABVX) is trading at is $13.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.